

**Supplementary Table 1 Univariate analysis of prognostic factors**

Variable	No.	2-year OS (%)	<i>p</i>	2-year PFS (%)	<i>p</i>	2-year LRPFS (%)	<i>p</i>	2-year DPFS (%)	<i>p</i>
All patients	106	58.2		41.6		76.8		67.1	
Age									
≥60	51	49.2	0.10	40.2	0.46	77.6	0.49	59.4	0.13
<60	55	66.5		42.3		76.3		73.8	
Sex									
Male	90	55.4	0.079	36.4	0.026	74.0	0.18	63.3	0.074
Female	16	74.0		68.8		87.5		86.5	
Location of primary esophageal cancer									
Cervix	23	68.2	0.32	60.9	0.29	89.8	0.47	69.6	0.39
Upper 1/3 esophagus	31	59.9		42.6		70.4		72.1	
Middle 1/3 esophagus	46	54.7		34.3		76.7		66.5	
Lower 1/3 esophagus	6	31.3		22.2		50.0		33.3	
Clinical stage of primary esophageal cancer									
I-II	14	76.9	0.33	51.1	0.14	70.3	0.84	85.1	0.11
III-IV	92	55.3		40.2		78.3		64.4	
KPS									
≥90	87	57.3	0.95	37.9	0.83	73.7	0.56	66.3	0.69
<90	19	62.3		57.0		88.5		71.5	

Smoking									
Yes	72	55.3	0.22	36.1	0.20	74.0	0.63	62.6	0.28
No	34	64.5		52.6		82.2		75.9	
Drinking									
Yes	49	44.7	0.12	29.0	0.078	82.0	0.31	54.9	0.067
No	57	69.0		52.4		71.0		77.0	
Family history									
Yes	23	62.4	0.61	37.0	0.70	63.8	0.19	70.7	0.24
No	83	58.7		42.6		80.4		65.5	
BMI									
<18.5	18	48.0	0.20	34.9	0.49	74.6	0.39	51.6	0.21
≥18.5	88	60.0		42.4		77.2		69.8	
Concurrent chemotherapy									
TP/PF	96	59.6	0.64	41.4	0.55	75.1	0.13	67.7	0.82
5-FU/platinum	10	42.2		42.9		100		60.0	
Induction chemotherapy									
Yes	32	51.8	0.59	42.1	0.58	77.1	0.65	59.7	0.94
No	74	60.2		40.9		77.0		69.4	
RT technique									
3D-CRT	29	53.8	0.59	39.7	0.76	70.6	0.62	60.2	0.39
IMRT/VMAT	77	60.1		41.8		79.7		69.7	
RT dose for primary									

esophageal cancer									
≥60 Gy	75	62.2	0.21	41.9	0.60	77.5	0.56	71.5	0.068
<60 Gy	31	49.2		46.1		77.1		58.5	
Location of second primary									
cancer									
Esophagus	43	48.8	0.85	27.8	0.91	61.2	0.46	66.7	0.43
Hypopharynx	8	58.3		33.3		62.5		50.0	
Stomach	2	100		0		0		100	
Clinical stage of second									
primary cancer									
I-II	34	51.0	0.94	26.6	0.34	56.6	0.36	64.1	0.95
III-IV	19	47.8		28.1		64.4		63.6	
RT dose for second									
primary cancer									
≥60 Gy	33	52.6	0.66	21.9	0.42	59.3	0.50	63.8	0.94
<60 Gy	23	53.7		50.1		63.6		67.7	

---

OS: overall survival; PFS: progression-free survival; LRPFS: locoregional progression-free survival; DPFS: distant progression-free survival; KPS:

Karnofsky performance scale; BMI: body mass index; TP: taxane+ platinum; 5-FU: 5-fluorouracil; RT: radiotherapy; 3D-CRT: three-dimensional

conformal radiotherapy; IMRT: intensity modulated radiotherapy; VMAT: volumetric modulated arc therapy; CRT: chemoradiotherapy.